Join to view full profile
13400 E Shea BlvdScottsdale, AZ 85259
Phone+1 480-301-8000
Dr. Palmer is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 2005 - 2008
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2001 - 2004
New York Medical CollegeClass of 2001
Certifications & Licensure
AZ State Medical License 2013 - 2028
WI State Medical License 2008 - 2013
NC State Medical License 2005 - 2008
NY State Medical License 2003 - 2005
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Inpatient - Core EMR, Epic Systems Corporation, 2013-2015, 2017
- CMS Meaningful Use Stage 2 Certification HealtheLife and PowerChart, Cerner Corporation, 2013-2015, 2017
- CMS Meaningful Use Stage 2 Certification FirstNet (CQM), Cerner Corporation, 2013-2015, 2017
Clinical Trials
- Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
- Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation Start of enrollment: 2021 Jan 14
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- Acute Myeloid Leukemia Subtype-Specific Prognostic Value of NGS in the Setting of Intensive Chemotherapy.Abiola Bolarinwa, Aref Al-Kali, Hassan B Alkhateeb, Abhishek A Mangaonkar, Antoine N Saliba
American Journal of Hematology. 2026-10-01 - Risk-Adjusted Comparison of Survival in Chronic Myelomonocytic Leukemia With and Without Allogeneic Stem Cell Transplant: Mayo Clinic Experience in 775 Consecutive Pat...Ali Alsugair, Saubia Fathima, Mohammad M Alhousani, Estefania Gauto Mariotti, Abiola Bolarinwa
American Journal of Hematology. 2026-10-01 - Venetoclax Plus Hypomethylating Agent for 7- Versus 14- Versus 21- Versus 28-Day Cycles in Newly-Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk-Stratified...Sudhesh Kumar, Momna Warraich, Mahnoor Fatima, Kristen McCullough, Aref Al-Kali
American Journal of Hematology. 2026-09-17
Press Mentions
CTI BioPharma Presents New Anemia Benefit Data from Pacritinib Program at the 2022 American Society of Hematology (ASH) Annual Meeting and ExpositionDecember 11th, 2022- Pacritinib Approved for Intermediate- or High-Risk Myelofibrosis with ThrombocytopeniaMarch 3rd, 2022
Fighting Leukemia Then Joining the TeamAugust 2nd, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: